Sun Pharmaceutical Industries Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Dilip Shanghvi
Chief executive officer
₹60.5m
Total compensation
CEO salary percentage | 75.6% |
CEO tenure | 31.3yrs |
CEO ownership | 9.6% |
Management average tenure | 2.5yrs |
Board average tenure | 3.2yrs |
Recent management updates
Recent updates
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?
Apr 09Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00
Feb 02Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?
Feb 02CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | ₹61m | ₹46m | ₹96b |
Dec 31 2023 | n/a | n/a | ₹89b |
Sep 30 2023 | n/a | n/a | ₹85b |
Jun 30 2023 | n/a | n/a | ₹84b |
Mar 31 2023 | ₹55m | ₹41m | ₹85b |
Dec 31 2022 | n/a | n/a | ₹42b |
Sep 30 2022 | n/a | n/a | ₹41b |
Jun 30 2022 | n/a | n/a | ₹39b |
Mar 31 2022 | ₹51m | ₹38m | ₹33b |
Dec 31 2021 | n/a | n/a | ₹64b |
Sep 30 2021 | n/a | n/a | ₹62b |
Jun 30 2021 | n/a | n/a | ₹60b |
Mar 31 2021 | ₹46m | ₹35m | ₹29b |
Dec 31 2020 | n/a | n/a | ₹24b |
Sep 30 2020 | n/a | n/a | ₹15b |
Jun 30 2020 | n/a | n/a | ₹7b |
Mar 31 2020 | ₹43m | ₹32m | ₹38b |
Dec 31 2019 | n/a | n/a | ₹40b |
Sep 30 2019 | n/a | n/a | ₹43b |
Jun 30 2019 | n/a | n/a | ₹30b |
Mar 31 2019 | ₹263k | ₹1 | ₹27b |
Dec 31 2018 | n/a | n/a | ₹34b |
Sep 30 2018 | n/a | n/a | ₹24b |
Jun 30 2018 | n/a | n/a | ₹36b |
Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensation vs Market: Dilip's total compensation ($USD723.23K) is below average for companies of similar size in the Indian market ($USD1.22M).
Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.
CEO
Dilip Shanghvi (69 yo)
31.3yrs
Tenure
₹60,541,920
Compensation
Mr. Dilip Shantilal Shanghvi serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He serves as Managing Director & Director at Sun Petrochemic...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 396.1b | |
Executive VP | no data | ₹68.75m | 0.12% ₹ 4.9b | |
Chief Financial Officer | 7.1yrs | ₹38.89m | no data | |
Executive Vice-President of Global Operations | no data | no data | no data | |
EVP & Chief Information Officer | less than a year | no data | no data | |
VP, Head of Investor Relations & Strategic Projects | no data | no data | no data | |
Company Secretary & Compliance Officer | 2.5yrs | no data | no data | |
Director of Corporate Development | no data | ₹65.30m | no data | |
Chief Human Resources Officer | less than a year | no data | no data | |
Head of India Business | no data | no data | no data | |
Chief Executive Officer of North America Business | 7.9yrs | no data | no data | |
Head of Corporate Relations & CSR - India Regulatory Affairs | no data | no data | no data |
2.5yrs
Average Tenure
60yo
Average Age
Experienced Management: SUNPHARMA's management team is considered experienced (2.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD & Chairman of the Board | 31.3yrs | ₹60.54m | 9.6% ₹ 396.1b | |
Executive VP | 1.1yrs | ₹68.75m | 0.12% ₹ 4.9b | |
Non-Executive & Non-Independent Director | 30.5yrs | ₹2.20m | 1.8% ₹ 74.2b | |
Non-Executive & Independent Director | 3.2yrs | ₹5.10m | no data | |
Non-Executive Independent Director | 6.2yrs | ₹7.80m | 0.00033% ₹ 13.6m | |
Independent Director | 1.1yrs | ₹3.20m | no data | |
Lead Independent Director | 3.2yrs | ₹8.50m | no data | |
Independent Director | 1.7yrs | ₹4.80m | no data |
3.2yrs
Average Tenure
67.5yo
Average Age
Experienced Board: SUNPHARMA's board of directors are considered experienced (3.2 years average tenure).